Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc.

ALPHAEON is a healthcare company that develops and provides aesthetic products and medical devices for healthcare professionals and patients

ALPHAEON

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.

Cordia Pharma LTD UK operates in the healthcare industry, providing business process optimization, technology solutions, strategic sourcing, and digital transformation services. This description is self-described.

Cordia Pharma LTD UK

Gilead Oncology

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives.

Social Media Guidelines: https://www.gilead.com/social-media-guidelines

Tango Therapeutics

Tmunity Therapeutics

Vaccitech

AlloVir

Corus Pharma

Allogene Therapeutics

Arcus Biosciences

Pardes Biosciences

Galapagos

Gritstone bio

Precision BioSciences

Hookipa Pharma

Venrock

Gilead Sciences

Gilead is the second-largest biotech employer in the Bay Area and has grown considerably over the last four years. In this piece, Chairman and Chief Executive Officer Daniel O'Day talks about the company’s evolution, philanthropic culture and commitment to the local community.

#GileadNews: We announced today that we're acquiring CymaBay Therapeutics, reinforcing our long-standing commitment to liver disease. We'll continue advancing a potential therapy for primary biliary cholangitis, a rare and chronic liver disease that impairs liver function and quality of life. Read the press release and important information: https://gilead.inc/48baEtP

We’re proud to be on the list of #AmericasMostJUST companies, and for being ranked #5 in our industry. We were recognized for our work helping to make the world a healthier place for all people while fulfilling our responsibilities as a good corporate citizen.

Read more here: https://gilead.inc/3SzbVFh

#JUST100

This year’s theme for National Black HIV/AIDS Awareness Day is “Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities.” We spoke with C. Virginia Fields, President and CEO of National Black Leadership Commission on Health (Black Health), a Gilead grantee, about how together, we can take action toward meaningful change. 
 
We commend Virginia and our many community partners for continuing to honor and advance the decades of progress that Black communities have made in #HIV.  
 
Learn more: https://gilead.inc/487PjBu

#NBHAAD

#GileadNews: Our Q4 and Full Year 2023 Financial Results are now available. Read the press release: https://gilead.inc/3HNMQl9

#earnings

We know that there can only be true progress in scientific innovation when it's accessible to those who need it most. That's why we're working to address disparities in care for people around the world.
  
#WorldCancerDay | #CloseTheCareGap

For many people living with #cancer, hearing about the experiences of others can be helpful. Dale, who is living with #breastcancer, shares her journey and point of view about how sharing information can help reduce health disparities. 

#WorldCancerDay | #CloseTheCareGap

#GileadNews: Ted W. Love, MD joins Gilead Sciences’ Board of Directors. https://gilead.inc/3UoE04A

We're committed to amplifying Black voices and inspiring an inclusive culture that drives innovation. Learn more about inclusion and diversity at Gilead. https://gilead.inc/3UguIrw

#BlackHistoryMonth | #BHM | #GileadLife

We embed Environmental, Social and Governance (ESG) criteria into our value chain and core business operations to drive value for the communities we serve. In partnership with Reuters, we’ve developed a white paper on how purpose-driven ESG integration can address unmet needs, ensure health equity and promote a holistic approach to healthcare.

Reuters Events Sustainable Business #ESG

Metric
Company Name	Gilead Sciences, Inc.	ALPHAEON	Axsome Therapeutics, Inc.	Cordia Pharma LTD UK
Symbol	GILD		AXSM
MSH ID	COM:GILEAD	COM:ALPHAEON	COM:AXSOME	COM:CORDIAPHARMA
Market	STOCKS	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare	Commercial & Professional Services
Industry	Drug Manufacturers - General	Medical Devices and Aesthetics	Biotechnology	Healthcare & Health Services
Country	US	US	US	GB
Stage			Post-IPO Equity
Employee Count	18K		569
Website	gilead.com	alphaeon.com	axsome.com	cordiapharma.com
LinkedIn	gilead-sciences			cordia-pharma-ltd
Founders

Metric
Market Cap	85.65B	3.92B
Enterprise Value
Monthly Web Traffic		7.82K
Web Traffic Growth		-0.74
Valuation
Raised Capital		225M

Metric
Revenue	27.12B	270.60M
Revenue (LTM)
Revenue (NTM)
Gross Profit	27.12B	237.70M
EBITDA	7.61B	-176.07M
Operating Income	7.61B	-182.91M
Net Income	5.67B	-239.24M
EPS	4.54	-5.27
Diluted EPS	4.50	-5.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.78	0.90
Operating Profit Margin	0.36	-0.86
EBITDA Margin	0.28	-0.65
Net Profit Margin	0.21	-0.88
Return on Equity	0.26	-1.12
Return on Assets	0.09	-0.41
Return on Capital Employed	0.24	-0.52

COM:GILEAD

Gilead Sciences, Inc.

Last Close

89.76

22/11 21:00

Market Cap

85.65B

Beta: -

Volume Today

4.43M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	16.30	-20.81
P/B Ratio	4.31	16.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.91	16.65
EV Multiple	23.26	-11.57

Metric
Days Sales Outstanding	63.83	128.09
Days Payables Outstanding	36.85	506.28
Days Inventory Outstanding	205.86	229.29
Operating Cycle	268.59	383.54
Cash Conversion Cycle	262.69	-229.81
Asset Turnover	0.52	0.53

Metric
Operating Cash Flow	8.01B	-145.08M
Free Cash Flow	7.42B	-145.66M
Cash Flow to Debt	0.34	-0.81
Operating Cash Flow/Sales	0.31	-0.54
Free Cash Flow Yield	0.08	-0.03

Metric
Cash & Equivalents	6.08B	386.19M
Accounts Receivable	157M	-57.12M
Inventory	3.37B	15.13M
Goodwill	8.31B	12.04M
Debt to Capitalization	0.60	0.65
Debt to Assets	0.42	0.31
Current Ratio	1.34	4.46
Quick Ratio	1.08	3.46

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	0.24
R&D to Revenue	0.21	0.37
SG&A to Revenue		0.44